Endothelin receptor antagonists

US5883090A · kind A · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Dieter Dorsch · Ober-Ramstadt, DE
• Mathias Osswald · Zwingenberg, DE
• Werner Mederski · Zwingenberg, DE
• Claudia Wilm · Darmstadt, DE
• Claus J. Schmitges · Groß-Umstadt, DE
• Maria Christadler · Darmstadt, DE

Key dates

• Filing date: Jun 6, 1997
• Grant date: Mar 16, 1999
• Expiry date: Jun 6, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to pyridizinone derivatives of formula I ##STR1## wherein the various substituents are defined in the specification, and salts thereof, which have useful pharmacological properties, in particular endothelin receptor-antagonistic properties. The compounds are thus useful for the treatment of illnesses associated with endothelin activities, such as hypertension, cardiac insufficiency, coronary heart disease, renal, cerebral and myocardial ischaemia, renal insufficiency, cerebral infarct, subarachnoid haemorrhage, arteriosclerosis pulmonary high blood pressure, inflammations, asthma, prostate hyperplasia, endotoxic shock and in complications after the administration of immunosuppressants which produce renal vasoconstriction.